What is the market's earnings forecast for Precipio next quarter?

What were the key takeaways from Precipio’s earnings call?

Did Precipio beat or miss consensus estimates last quarter?

What is Precipio's gross profit margin?

What is the revenue and EPS growth rate for Precipio year over year?

What factors drove the changes in Precipio's revenue and profit?

What were the key takeaways from Precipio's earnings call?

What is Precipio's latest dividend and current dividend yield?

- **Breakthrough Profitability**: Achieved $0.5 million EBITDA and $0.285 million cash from operations, ending reliance on external capital.
- **Revenue Surge**: 30% YoY growth to $6.8 million, with Pathology Services up 20% QoQ and Products Division up 16% QoQ.
- **Margin Expansion**: Pathology Services gross margin at 46%, total company margin at 44%, targeting >50% by mid-2026.
- **Strategic Shift**: Transitioning from cost-cutting to growth investments, including $120,000 lab expansion and technical support roles.
- **Shareholder Value**: Share price tripled year-to-date, with plans to leverage market cap growth for strategic opportunities.

**【CEO Summary Section】**
- **Financial Milestones**: Achieved first-time positive adjusted EBITDA of $469,000 and $285,000 in cash from operations, marking a $433,000 positive cash swing from Q2. Share price has tripled since the start of 2025.
- **Revenue Growth**: Total Q3 revenue reached $6.8 million (30% YoY, 20% QoQ), driven by:
  - **Pathology Services**: $6 million (20% QoQ growth, 46% gross margin up from 43%)
  - **Products Division**: $720,000 (16% QoQ growth, 30% YoY expansion)
- **Gross Margin Expansion**: Overall gross margin improved to 44%, with Pathology Services leading at 46%. Expecting >50% gross margin by mid-2026.
- **Strategic Investments**: 
  - $120,000 annual lab space expansion to separate clinical and product operations
  - Technical support specialist to accelerate customer onboarding, generating $50,000 incremental QoQ revenue
- **Operational Efficiency**: Absorbed 20% revenue growth in Pathology Services without significant fixed cost increases, maintaining margin expansion.
- **Future Priorities**: 
  - Double-digit growth in both divisions
  - Expand margins through scale
  - Invest cash in strategic partnerships and product innovation
  - Enhance investor engagement to drive share price appreciation

Precipio, Inc.(PRPO)-20251118-2025 Q3 Earnings call transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

PRPO

PRPO fundamentals

You can ask Aime